悦心健康：2025年前三季度净利润约308万元

Group 1 - The core viewpoint of the article highlights the financial performance of Yuexin Health in Q3, with a revenue of approximately 771 million yuan, representing a year-on-year decrease of 13.23% [1] - The net profit attributable to shareholders increased to approximately 3.08 million yuan, showing a significant year-on-year growth of 109.33% [1] - Basic earnings per share rose to 0.0034 yuan, reflecting an increase of 109.5% compared to the previous year [1] Group 2 - The article also discusses the broader biopharmaceutical market, noting that China has sold overseas authorizations worth 80 billion USD this year [1] - It raises questions about the disparity between the hot secondary market and the cooling fundraising environment in the primary market for biopharmaceuticals [1]